DBV Technologies (NASDAQ:DBVT) Shares Gap Up – Still a Buy?

DBV Technologies S.A. (NASDAQ:DBVT) gapped up before the market opened on Monday. The stock had previously closed at $9.75, but opened at $10.11. DBV Technologies shares last traded at $9.9350, with a volume of 38,862 shares trading hands.

Analysts Set New Price Targets

A number of research firms have recently weighed in on DBVT. Wall Street Zen lowered shares of DBV Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 4th. Citigroup reaffirmed a “market outperform” rating on shares of DBV Technologies in a research report on Wednesday, September 30th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of DBV Technologies in a research report on Thursday, October 15th. Citizens Jmp lifted their price objective on DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a research note on Tuesday, June 30th. Finally, HC Wainwright reissued a “buy” rating on shares of DBV Technologies in a report on Tuesday, June 30th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, DBV Technologies presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.50.

DBV Technologies Trading Up 2.3%

The stock has a market capitalization of $627.48 million, a price-to-earnings ratio of -2.84 and a beta of -1.04. The stock has a 50-day moving average price of $11.95 and a 200 day moving average price of $15.38.

Institutional Trading of DBV Technologies

Several institutional investors have recently bought and sold shares of the business. Royal Bank of Canada increased its position in shares of DBV Technologies by 167.1% in the first quarter. Royal Bank of Canada now owns 4,680 shares of the company’s stock valued at $98,000 after buying an additional 2,928 shares in the last quarter. Vontobel Holding Ltd. acquired a new position in DBV Technologies during the third quarter worth $144,000. Personal CFO Solutions LLC purchased a new stake in shares of DBV Technologies during the first quarter worth about $264,000. Cetera Investment Advisers lifted its stake in DBV Technologies by 93.4% in the 1st quarter. Cetera Investment Advisers now owns 25,358 shares of the company’s stock valued at $530,000 after buying an additional 12,243 shares in the last quarter. Finally, AdvisorShares Investments LLC purchased a new position in DBV Technologies in the 1st quarter valued at about $1,052,000. 71.74% of the stock is owned by institutional investors and hedge funds.

About DBV Technologies

DBV Technologies SA (NASDAQ: DBVT) is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s approach is based on epicutaneous immunotherapy, which is designed to deliver small amounts of an allergen through the skin to help desensitize the immune system.

DBV Technologies’ lead product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.